Evidence mapPaperPMID 40859967Full record

ReviewDrug design, development and therapy2025

Traditional Chinese Medicine Monomers and Their Derivatives as a Promising Therapeutic Tool for Hepatocellular Carcinoma by Activation of Mitophagy.

Jiayu Zhu, Sihan Yin, Shengping Luo, Fei Yu, Kewei Sun

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiayu Zhu *The First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Sihan Yin *Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Shengping LuoSchool of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Fei YuThe First Clinical College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Kewei SunDepartment of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor of the liver. Treatment programs according to its physiological and pathological characteristics have reduced the number of new cases and deaths of HCC, but the morbidity and mortality are still high, posing a significant threat to human health. In recent years, the importance of mitophagy in the treatment of HCC has gradually been recognized. The activation of mitophagy inhibits the survival, proliferation and migration of HCC cells through a variety of pathways, promotes cell apoptosis, and can also reduce drug resistance, providing a new direction for the treatment of HCC. Studies have shown that Traditional Chinese medicine (TCM) monomers and their derivatives can improve the therapeutic efficacy of HCC and slow down disease progression by regulating mitophagy. This article summarizes the potential mechanism of mitophagy in the progression of HCC and comprehensively explores the potential of TCM monomers and their derivatives in the treatment of HCC, providing new perspectives and strategies for clinical treatment.

Indexed as

Antineoplastic Agents, PhytogenicCarcinoma, HepatocellularDrugs, Chinese HerbalLiver NeoplasmsMedicine, Chinese TraditionalMitophagyApoptosisCell ProliferationHumansAntineoplastic Agents, PhytogenicDrugs, Chinese Herbalderivativeshepatocellular carcinomamitophagytraditional Chinese medicine monomers

Identifiers

PMID40859967
PMCPMC12374703

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.